Short Interest in FibroGen, Inc. (NASDAQ:FGEN) Declines By 5.2%

FibroGen, Inc. (NASDAQ:FGEN - Get Free Report) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 2,910,000 shares, a decline of 5.2% from the January 15th total of 3,070,000 shares. Based on an average trading volume of 1,250,000 shares, the days-to-cover ratio is presently 2.3 days.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Two Sigma Securities LLC bought a new position in shares of FibroGen in the fourth quarter worth $27,000. Velan Capital Investment Management LP bought a new position in FibroGen in the fourth quarter valued at $42,000. XTX Topco Ltd increased its stake in FibroGen by 423.8% in the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company's stock valued at $51,000 after acquiring an additional 77,693 shares during the last quarter. Franklin Street Advisors Inc. NC increased its stake in FibroGen by 100.0% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company's stock valued at $106,000 after acquiring an additional 100,000 shares during the last quarter. Finally, FMR LLC increased its stake in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company's stock valued at $153,000 after acquiring an additional 68,569 shares during the last quarter. Institutional investors own 72.71% of the company's stock.

FibroGen Trading Down 8.6 %

Shares of FibroGen stock traded down $0.07 during trading on Friday, hitting $0.71. The stock had a trading volume of 9,359,819 shares, compared to its average volume of 4,885,358. The firm has a market cap of $71.13 million, a price-to-earnings ratio of -0.57 and a beta of 0.75. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.80. The business's 50-day moving average is $0.52 and its 200 day moving average is $0.43.

Analyst Upgrades and Downgrades

FGEN has been the topic of a number of analyst reports. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of FibroGen in a report on Thursday. StockNews.com initiated coverage on shares of FibroGen in a report on Friday. They set a "hold" rating on the stock. Finally, William Blair reissued a "market perform" rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.